References
- Baldwin RM, Shultz MA, Buckpitt AR. Bioactivation of the pulmonary toxicants naphthalene and 1-nitronaphtalene by rat CYP2F4. Journal of Pharmacology and Experimental Therapeutics 2005; 312(2)857–865
- Carr BA, Wan J, Hines RN, Yost GS. Characterization of the human lung CYP2F1 gene and identification of a novel lung-specific binding motif. Journal of Biological Chemistry 2003; 278: 15473–15483
- Chen N, Whitehead SE, Caillat AW, Gavit K, Isphording DR, Kovacevic D, McCreary MB, Hoffman SM. Identification and cross-species comparisons of CYP2F subfamily genes in mammals. Mutation Research 2002; 499: 155–161
- Hukkanen J, Pelkonen O, Raunio H. Expression of xenobiotic-metabolizing enzymes in human pulmonary tissue: Possible role in susceptibility for ILD. European Respiratory Journal 2001; 18(32)122–126
- Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. Journal of Internal Medicine 2001; 250: 186–200
- Jiang JH, Li Z, Su G, Jia WH, Zhang RH, Yu XJ, Zhang M, Wen JM, Zeng YX. Study on genetic polymorphisms of CYP2F1 gene in Guangdong population of China. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2006; 23(4)383–387
- Lanza DL, Code E, Crespi CL, Gonzalez FJ, Yost GS. Specific dehydrogenation of 3-methylindole and epoxidation of naphthalene by recombinant human CYP2F1 expressed in lymphoblastoid cells. Drug Metabolism and Disposition 1999; 27: 798–803
- Lanza DL, Yost GS. Selective dehydrogenation/oxygenation of 3-methylindole by cytochrome p450 enzymes. Drug Metabolism and Disposition 2001; 29: 950–953
- Nakajima T, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, Aoyama T. Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450. Chemical Research in Toxicology 1994; 7: 891–896
- Nebert DW, Menon AG. Pharmacogenomics, ethnicity, and susceptibility genes. Pharmacogenomics Journal 2001; 1: 19–22
- Nhamburo PT, Kimura S, Mcbride OW, Kozak CA, Gelboin H, Gonzalez FJ. The human CYP2F gene subfamily: identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression, and chromosome mapping. Biochemistry 1990; 29: 5491–5499
- Nichols WK, Mehta R, Skordos K, Macé K, Pfeifer AMA, Carr BA, Minko T, Burchiel SW, Yost GS. 3-Methylindole-induced toxicity to human bronchial epithelial cell lines. Toxicological Sciences 2003; 71: 229–236
- Pelkonen O, Raunio H. Metabolic activation of toxins: tissue-specific expression and metabolism in target organs. Environmental Health Perspectives 1997; 105(4)767–774
- Rendic S. Summary of information on human CYP enzymes: Human cytochrome P450 metabolism data. Drug Metabolism Reviews 2002; 34: 83–448
- Sheets PL, Yost GS, Carlson GP. Benzene metabolism in human lung cell lines BEAS-2B and A549 and cells overexpressing CYP2F1. Journal of Biochemical and Molecular Toxicology 2004; 18: 92–99
- Tournel G, Cauffiez C, Billaut-Laden I, Allorge D, Chevalier D, Bonnifet F, Mensier E, Lafitte J-J, Broly F, Lo-Guidice J-M. Molecular analysis of the CYP2F1 gene: Identification of a frequent loss non functional allelic variant. Mutation Research 2007; 617(1–2)79–89
- Wang H, Lanza D, Yost G. Cloning and expression of CYP2F3 a cytochrome P450 that bioactivates the selective pneumotoxins 3-methylindole and naphthalene. Archives in Biochemistry and Biophysics 1998; 349: 894–900